Axxess Pharma, Inc. Reports $1.3 Million in Annual Sales From Non-Constipating Multi-Vitamin Triferrex 150
16 August 2010 - 10:00PM
Marketwired
Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company
specializing in the marketing and distribution of both prescription
and non-prescription medical products, is pleased to report they
have generated $1.3 million in annual sales from their
non-constipating multi-vitamin Triferrex 150.
Patients and individuals around the world frequently experience
constipation from multi-vitamins due to high iron and calcium
contents. This uncomfortable feel often times makes patients and
individuals refuse to take the multi-vitamins that are needed to
keep them healthy or return to health. This action then places the
patient in further harm. Triferrex 150 helps eliminate this problem
by providing the careful balance of required nutrients while
preventing constipation.
"Sales for Triferexx 150 have surpassed our expectations. We
forecasted $1 million in sales for 2009 and ended with $1.3
million. We anticipate 2010 sales of Triferrex 150 to exceed that
of 2009. The Specialists and the general practitioners have
accepted Triferexx 150 as a safe and a well tolerated Iron
supplement than the other iron preparations in the market.
Triferexx 150 is prescribed by the leading nephrologistas, a
hematenic of choice in conjunction with Eperex at the dialysis
clinics," stated Gerald Sequeira, President/CEO.
For more information, please contact Investor Relations at (973)
351-3868.
About Axxess Pharma, Inc.: Axxess Pharma, Inc. is a specialty
pharmaceutical company that focuses on the marketing of
dermatological, therapeutic nutritionals, pain management and
diagnostic products in Canada and abroad since 1997. Axxess owns 22
established pharmaceutical prescription products that have proven
sales in Canada and internationally. The company has an experienced
management team and field sales force to market products nationally
to hospitals and retail pharmacies as well as specialized practice
areas including Dermatology and Nephrology, Neurology and
Urology.
Safe Harbor Statements about the Company's future expectations
and all other statements in this press release other than
historical facts, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934, and as that term is defined
in the Private Securities Litigation Reform Act of 1995. The
Company intends that such forward-looking statements be subject to
the safe harbors created thereby.
The above information contains information relating to the
Company that is based on the beliefs of the Company and/or its
management, as well as assumptions made by any information
currently available to the Company or its management. When used in
this document, the words "anticipate," "estimate," "expect,"
"intend," "plans," "projects," and similar expressions, as they
relate to the Company or its management, are intended to identify
forward-looking statements. Such statements reflect the current
view of the Company regarding future events and are subject to
certain risks, uncertainties and assumptions, including the risks
and uncertainties noted. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
to be incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated, expected,
intended or projected. In each instance, forward-looking
information should be considered in light of the accompanying
meaningful cautionary statements herein. Factors that could cause
results to differ include, but are not limited to, successful
performance of internal plans, the impact of competitive services
and pricing and general economic risks and uncertainties.
Contact: Taylor Capitol, Inc. Investor Relations Stephen Taylor
973-351-3868 Info@TheStockAlerts.com www.TheStockAlerts.com
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jul 2023 to Jul 2024